Millions of people in India and the world over suffer from gastroesophageal disorders – from acid reflux and GERD to functional dyspepsia and gastroparesis – significantly impacting their quality of life. But many patients suffer for years without a drug that treats both the acid overproduction and motility dysfunction that are the basis of their symptoms. PANTOSTRUM DSR Steris Healthcare Pvt Ltd A well-designed, fixed dose combination (FDC) delayed-release capsule that blends two potent clinical molecules, Domperidone 30mg and Pantoprazole 40mg is a dual-action medication widely prescribed for the management of severe acid reflux, Gastroesophageal Reflux Disease (GERD), and peptic ulcer-related conditions.

Why Domperidone 30mg + Pantoprazole 40mg is important in modern GI management

In India, gastrointestinal disorders related to acid are one of the most common chronic conditions seen in clinical practice. Gastroesophageal reflux disease (GERD), functional dyspepsia, peptic ulcer disease, and gastroparesis affect hundreds of millions of people and impose a huge burden on patients and healthcare systems.

The problem with treating these conditions is that they rarely have one single cause. Acid hypersecretion and delayed gastric emptying are often seen together, so proton pump inhibitors alone are often insufficient. This is exactly the gap that PANTOSTRUM DSR fills. PANTOSTRUM DSR provides two different but synergistic routes to complete gastric relief. Pantoprazole 40mg, one of the most potent and selective proton pump inhibitors (PPIs) and Domperidone 30mg, a highly effective prokinetic and antiemetic agent.

The delayed-release capsule ensures that Pantoprazole reaches the small intestine intact, protecting it from degradation by gastric acid and ensuring maximum bioavailability. Domperidone, on the other hand, increases gastric motility, reduces nausea, and increases the tone of the lower oesophageal sphincter (LES).

What are the benefits of Domperidone 30mg + Pantoprazole 40mg?

• Dual-action gastric relief: Pantoprazole suppresses acid production at the source while Domperidone improves gastric emptying and motility — addressing both the cause and the symptoms of acid-related disorders simultaneously.
• Superior GERD control: The combination achieves faster and more complete relief of heartburn, regurgitation, and chest discomfort compared to PPI monotherapy, especially in patients with concurrent motility issues.
• Powerful antiemetic action: Domperidone's dopamine D2 receptor antagonism effectively controls nausea and vomiting — symptoms that significantly impair quality of life in GERD and gastroparesis patients.
• Accelerated gastric emptying: Domperidone promotes coordinated gastric and duodenal motility, reducing bloating, early satiety, and postprandial fullness — key complaints in functional dyspepsia.
• Lower oesophageal sphincter strengthening: Domperidone increases LES pressure, mechanically reducing acid reflux episodes and protecting the oesophageal mucosa from repeated acid damage.
• Potent and selective acid suppression: Pantoprazole is a second-generation PPI that irreversibly blocks the H⁺/K⁺-ATPase enzyme (proton pump) in gastric parietal cells — achieving over 90% acid suppression and maintaining gastric pH above 4 for extended periods.
• Mucosal healing: By reducing acid exposure time, Pantoprazole facilitates healing of oesophageal erosions, gastric ulcers, and duodenal ulcers.
• Delayed-release capsule advantage: The capsule format ensures optimal drug delivery — Pantoprazole's enteric-coated granules bypass the stomach intact, while the smooth capsule shell improves patient compliance.
• Once-daily convenience: A single PANTOSTRUM DSR capsule before breakfast provides all-day acid control and motility support, dramatically simplifying treatment and improving adherence.
• WHO-GMP certified quality: Manufactured by Steris Healthcare Pvt Ltd under stringent WHO-GMP certified conditions, ensuring consistent pharmaceutical-grade potency, purity, and safety.

Mechanism of action: how Domperidone 30mg + Pantoprazole 40mg works

 Pantoprazole 40mg

• Absorbed from the small intestine and transported to gastric parietal cells via the bloodstream
• Converted to an active sulphenamide in the acidic canaliculi of parietal cells
• Irreversibly binds to and inhibits the H⁺/K⁺-ATPase enzyme (proton pump)
• Blocks the final step of gastric acid secretion regardless of stimulus (food, gastrin, histamine)
• Maintains gastric pH >4 for 15–20 hours after a single dose
• Facilitates healing of acid-damaged mucosa — oesophagus, stomach, duodenum
• Selective for gastric H⁺/K⁺-ATPase — minimal off-target effects

 Domperidone 30mg

• Blocks dopamine D2 receptors in the gastric antrum, duodenum, and chemoreceptor trigger zone (CTZ)
• Removes dopamine's inhibitory effect on gastric motility → accelerates gastric emptying
• Coordinates antroduodenal contractions → reduces bloating and postprandial fullness
• Increases lower oesophageal sphincter (LES) tone → mechanically reduces acid reflux
• Blocks D2 receptors in the CTZ (outside the blood-brain barrier) → powerful antiemetic action
• Minimal CNS penetration → low risk of extrapyramidal side effects compared to metoclopramide
• Modified-release 30mg formulation provides sustained prokinetic and antiemetic action

Synergistic action: Pantoprazole neutralises excess acid production while Domperidone prevents acid from refluxing back into the oesophagus by improving gastric emptying and increasing LES pressure. Together, they provide comprehensive, multi-level gastric protection that neither drug achieves alone.

Indications, efficacy & clinical evidence: Domperidone 30mg + Pantoprazole 40mg

PANTOSTRUM DSR is indicated for adults with acid-related gastrointestinal disorders where both acid suppression and motility improvement are clinically required.

Primary indications

• Gastroesophageal reflux disease (GERD) — especially with coexisting delayed gastric emptying
• Functional dyspepsia — bloating, early satiety, postprandial fullness, epigastric discomfort
• Nausea and vomiting associated with gastric disorders
• Peptic ulcer disease — gastric and duodenal ulcers requiring acid suppression and motility support
• Gastroparesis with acid reflux symptoms
• Reflux oesophagitis — healing and maintenance of oesophageal mucosal integrity
• Zollinger-Ellison syndrome — pathological acid hypersecretion requiring high-dose PPI therapy
• Symptomatic relief in patients on NSAIDs or aspirin at risk of GI complications

Clinical evidence supporting Domperidone 30mg + Pantoprazole 40mg

• GERD symptom relief: Multiple randomised controlled trials (RCTs) demonstrate that the Domperidone + Pantoprazole combination achieves significantly faster and more complete relief of heartburn and regurgitation scores compared to pantoprazole monotherapy — particularly in patients with coexisting gastroparesis or delayed gastric emptying.
• Functional dyspepsia: Clinical studies show the combination significantly improves postprandial distress syndrome scores — reducing bloating, early satiety, and epigastric pain — compared to PPI alone, owing to Domperidone's prokinetic action.
• Mucosal healing rates: Pantoprazole 40mg achieves oesophageal mucosal healing rates of 85–95% at 8 weeks in erosive oesophagitis patients, with the addition of Domperidone reducing reflux episodes and thereby improving healing outcomes.
• Nausea and vomiting control: Domperidone's CTZ-mediated antiemetic action delivers measurable reduction in nausea and vomiting scores, improving patient quality of life and treatment adherence in GERD and dyspepsia management.
• 24-hour pH control: Pantoprazole 40mg maintains intragastric pH above 4 for a median of 15–20 hours per day — a critical threshold for oesophageal mucosal protection and symptom relief.
• Gastroparesis evidence: Domperidone has been extensively studied in diabetic and idiopathic gastroparesis, demonstrating significant improvements in gastric emptying time and symptom scores, making the combination particularly valuable for diabetic patients with both gastroparesis and GERD.

Side effects of PANTOSTRUM DSR (Domperidone 30mg + Pantoprazole 40mg)

Common side effects

• Headache: one of the most commonly reported side effects with Pantoprazole; usually mild and self-limiting.
• Diarrhoea or constipation: gastrointestinal motility changes may occur during initial weeks; Domperidone's prokinetic action may also alter bowel habits transiently.
• Dry mouth: mild xerostomia occasionally reported with Domperidone.
• Dizziness: mild and transient; more common during dose initiation.
• Flatulence and abdominal bloating: occasionally reported, particularly during the first week of therapy.
• Nausea: paradoxically, mild nausea may occur initially before Domperidone's full prokinetic effect establishes.
• Elevated prolactin levels (hyperprolactinaemia): Domperidone can increase prolactin secretion via pituitary D2 receptor blockade, potentially causing galactorrhoea, gynaecomastia, or menstrual irregularities with prolonged use.

Serious side effects of Domperidone 30mg + Pantoprazole 40mg

Seek immediate medical attention if you experience: chest pain, palpitations, irregular heartbeat, severe dizziness, muscle stiffness, uncontrolled muscle movements, signs of low magnesium (muscle cramps, seizures, irregular heartbeat), or severe skin reactions.

• QT interval prolongation (Domperidone): the most clinically significant serious risk. Domperidone can prolong the cardiac QT interval, particularly at higher doses or in patients with pre-existing cardiac conditions, electrolyte imbalances, or those on other QT-prolonging drugs. This risk is why PANTOSTRUM DSR should be used at the lowest effective dose for the shortest necessary duration.
• Ventricular arrhythmias: rare but potentially life-threatening cardiac arrhythmias (including ventricular tachycardia and torsades de pointes) have been reported with Domperidone. Use with extreme caution in patients with cardiac risk factors.
• Extrapyramidal symptoms: although rare with Domperidone (owing to limited CNS penetration), symptoms such as involuntary muscle movements, restlessness, or acute dystonia have been reported — more likely at higher doses or in very elderly patients.
• Hypomagnesaemia: long-term PPI use (Pantoprazole) can cause significant magnesium depletion, leading to muscle cramps, tremors, tetany, and cardiac arrhythmias. Monitor magnesium in patients on prolonged therapy.
• Clostridium difficile-associated diarrhoea: long-term PPI use alters gut microbiome and increases susceptibility to C. difficile infection — particularly in hospitalised or immunocompromised patients.
• Bone fracture risk: prolonged high-dose PPI use has been associated with increased risk of osteoporosis-related fractures (hip, wrist, spine). Calcium and Vitamin D supplementation should be considered in long-term users.
• Vitamin B12 deficiency: chronic Pantoprazole therapy can reduce gastric acid-dependent Vitamin B12 absorption, leading to deficiency over time. Periodic B12 monitoring is recommended.
• Severe hypersensitivity reactions: rare cases of anaphylaxis, Stevens-Johnson syndrome, and toxic epidermal necrolysis have been reported with PPIs. Discontinue immediately if a severe skin or allergic reaction occurs.

Available substitutes for PANTOSTRUM DSR (Domperidone 30mg + Pantoprazole 40mg)

• Other Domperidone 30mg + Pantoprazole 40mg FDC capsules from various Indian manufacturers (quality and bioavailability may vary)
• Domperidone 10mg + Omeprazole 20mg combinations — lower potency, standard-release formulations
• Domperidone 10mg + Rabeprazole 20mg DSR combinations — different PPI with similar prokinetic pairing
• Metoclopramide + PPI combinations — older prokinetic option with higher CNS side effect risk
• Itopride + PPI combinations — alternative prokinetic mechanism for functional dyspepsia
• PPI monotherapy (Pantoprazole 40mg alone) — for pure acid-related disorders without motility component

PANTOSTRUM DSR by Steris Healthcare provides the specific advantage of the higher 30mg Domperidone modified-release dose combined with Pantoprazole 40mg in a WHO-GMP certified delayed-release capsule — offering superior and sustained dual-action coverage. Always consult your physician before switching to any alternative.

Dosage guidelines for PANTOSTRUM DSR (Domperidone 30mg + Pantoprazole 40mg)

Administration: Take PANTOSTRUM DSR capsule 30–60 minutes before the first meal of the day (breakfast) for optimal efficacy. Swallow the capsule whole with a full glass of water — do not open, crush, or chew, as this destroys the delayed-release mechanism of Pantoprazole's enteric-coated granules.

Precautions & warnings: using PANTOSTRUM DSR (Domperidone 30mg + Pantoprazole 40mg)

Medical conditions requiring caution or contraindication

• Cardiac conditions: Domperidone must be used with extreme caution in patients with pre-existing QT prolongation, ventricular arrhythmias, significant cardiac disease, or electrolyte imbalances (hypokalaemia, hypomagnesaemia). ECG monitoring may be required.
• Hepatic impairment: Domperidone is extensively metabolised by the liver. Dose adjustment or avoidance is required in moderate to severe hepatic impairment. Pantoprazole dose should also be reduced in severe hepatic disease.
• Renal impairment: no dose adjustment is typically required for Pantoprazole in renal impairment, but Domperidone should be used cautiously and at longer dosing intervals in severe renal disease.
• Elderly patients: higher risk of QT prolongation with Domperidone and hypomagnesaemia with long-term Pantoprazole use. Use the lowest effective dose and monitor regularly.
• Gastrointestinal obstruction: Domperidone is contraindicated when stimulation of gastric motility could be dangerous — such as in mechanical GI obstruction, perforation, or GI haemorrhage.
• Pituitary tumours (prolactinoma): Domperidone raises prolactin levels and is contraindicated in patients with prolactin-dependent tumours.

Key drug interactions

• QT-prolonging drugs: Domperidone must never be combined with other QT-prolonging medications including certain antiarrhythmics (amiodarone, sotalol), antifungals (fluconazole, ketoconazole), macrolide antibiotics (erythromycin, clarithromycin), or antipsychotics. The risk of fatal cardiac arrhythmia is significantly increased.
• CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin): significantly increase Domperidone plasma levels — contraindicated combination due to amplified QT prolongation risk.
• Clopidogrel: Pantoprazole may reduce the antiplatelet efficacy of clopidogrel via CYP2C19 inhibition. If co-administration is unavoidable, physician supervision is essential.
• Methotrexate: PPIs including Pantoprazole may increase plasma levels of methotrexate, raising toxicity risk.
• Atazanavir / Nelfinavir (HIV antiretrovirals): absorption is reduced by Pantoprazole's acid suppression. Avoid co-administration.
• Digoxin: Domperidone may alter digoxin absorption; monitor digoxin levels closely.
• Anticholinergic drugs: antagonise Domperidone's prokinetic effect — reduced therapeutic efficacy when used together.

Contraindications

• Known hypersensitivity to Domperidone, Pantoprazole, benzimidazoles, or any capsule excipient
• Mechanical gastrointestinal obstruction, perforation, or GI haemorrhage
• Prolactin-dependent tumours (prolactinoma, certain breast cancers)
• Concomitant use with potent CYP3A4 inhibitors that also prolong QT interval
• Severe hepatic impairment
• Pregnancy: safety of Domperidone in pregnancy is not established; use only if clearly indicated and under specialist supervision
• Breastfeeding: Domperidone is excreted in breast milk and may affect the infant's cardiac function; avoid or use with specialist guidance

Conclusion

PANTOSTRUM DSR (Domperidone 30mg + Pantoprazole 40mg) by Steris Healthcare Pvt Ltd is a clinically advanced, dual-action delayed-release capsule that addresses the full spectrum of acid-related gastrointestinal disorders with precision and efficacy. By combining the irreversible proton pump inhibition of Pantoprazole 40mg with the prokinetic, antiemetic, and LES-strengthening action of Domperidone 30mg, PANTOSTRUM DSR delivers comprehensive gastric relief that neither agent alone can achieve.

From GERD and functional dyspepsia to peptic ulcer disease and gastroparesis, PANTOSTRUM DSR offers clinicians and patients a reliable, once-daily, WHO-GMP certified solution backed by robust clinical evidence. Used responsibly under medical supervision — with appropriate attention to cardiac monitoring, drug interactions, and duration of therapy — PANTOSTRUM DSR represents a significant advance in the management of complex gastroesophageal disorders in India and beyond.

 Frequently Asked Questions

1. What is domperidone 30mg pantoprazole 40mg for?

PANTOSTRUM DSR is used to treat acid-related gastrointestinal disorders including GERD (acid reflux), functional dyspepsia, nausea and vomiting, peptic ulcer disease, reflux oesophagitis, and gastroparesis. It contains Domperidone 30mg and Pantoprazole 40mg, working together to suppress acid production and improve gastric motility simultaneously.

2. How does Domperidone 30mg + Pantoprazole 40mg work?

Pantoprazole 40mg irreversibly blocks the proton pump (H⁺/K⁺-ATPase) in gastric parietal cells, suppressing acid production by over 90%. Domperidone 30mg blocks dopamine D2 receptors in the gut and chemoreceptor trigger zone, accelerating gastric emptying, increasing LES pressure to prevent reflux, and controlling nausea and vomiting. Together, they provide dual-level gastric protection.

3. When should I take domperidone 30mg pantoprazole 40mg capsule?

Take PANTOSTRUM DSR 30–60 minutes before breakfast, once daily or as prescribed. Taking it before food ensures Pantoprazole is activated and ready to suppress acid when proton pumps are most active during the meal. Swallow the capsule whole — do not open or crush it.

4. What is the difference between Domperidone 10mg and Domperidone 30mg in DSR capsules?

The standard Domperidone 10mg formulations provide immediate-release prokinetic action. The 30mg modified-release (DSR) formulation in PANTOSTRUM DSR is specifically designed for once-daily dosing, providing sustained and consistent prokinetic and antiemetic coverage throughout the day with a single capsule — improving compliance and reducing peak-related side effects.

5. Is domperidone 30mg pantoprazole 40mg safe for long-term use?

PANTOSTRUM DSR should be used for the shortest duration necessary to achieve therapeutic goals (typically 4–8 weeks). Long-term use requires physician supervision due to risks of hypomagnesaemia, Vitamin B12 deficiency, bone density reduction, and Domperidone-related QT prolongation. Regular monitoring of magnesium, B12, and cardiac status is recommended for long-term therapy.

6. Can domperidone 30mg pantoprazole 40mg cause heart problems?

Domperidone has a known potential to prolong the cardiac QT interval, particularly at higher doses or in patients with pre-existing cardiac conditions, electrolyte imbalances, or those taking other QT-prolonging drugs. This risk is managed by using the lowest effective dose, avoiding interacting drugs, and monitoring patients with cardiac risk factors. Always inform your physician of all medications and medical conditions before starting PANTOSTRUM DSR.

7. Can I take domperidone 30mg pantoprazole 40mg during pregnancy?

PANTOSTRUM DSR is generally not recommended during pregnancy as the safety of Domperidone in pregnancy is not fully established. If acid reflux or nausea management is required during pregnancy, consult your obstetrician for safer alternatives. Do not self-medicate with PANTOSTRUM DSR during pregnancy.

8. Why is domperidone 30mg pantoprazole 40mg given before meals and not after?

Pantoprazole works by blocking active proton pumps — these pumps are most active when stimulated by food. Taking the capsule 30–60 minutes before a meal ensures peak plasma Pantoprazole levels coincide with maximum proton pump activation, delivering the most effective acid suppression. Taking it after meals significantly reduces its efficacy.

9. Can I open the domperidone 30mg pantoprazole 40mg?

No. Never open, crush, or chew the capsule. Pantoprazole inside the capsule is formulated as enteric-coated granules that must reach the small intestine intact to dissolve. Opening the capsule exposes these granules to stomach acid, destroying Pantoprazole before it can be absorbed — resulting in significantly reduced efficacy and potential gastric irritation.

Quick reference: PANTOSTRUM DSR at a glance